Sager Omer, Beyzadeoglu Murat, Dincoglan Ferrat, Uysal Bora, Gamsiz Hakan, Demiral Selcuk, Oysul Kaan, Dirican Bahar, Sirin Sait
Dr. Omer Sager, Department of Radiation Oncology,, Gulhane Military Medical Academy and Medical Faculty,, Ankara 06018, Turkey, T: +903123044683, F: +903123044680,
Ann Saudi Med. 2014 Jan-Feb;34(1):54-8. doi: 10.5144/0256-4947.2014.54.
Surgery is the principal treatment for safely accessible hemorrhagic and symptomatic cavernous malformations. Nevertheless, the role of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) in the management of high-risk, symptomatic cavernoma lesions warrants further refinement. In this study, we evaluate the use of LINAC-based SRS for cerebral cavernous malformations (CMs) and report our 15-year single-center experience.
A retrospective study from the Department of Radiation Oncology and the Department of Neurosurgery at Gulhane Military Medical Academy and Medical Faculty, Ankara from April 1998 to June 2013.
Fifty-two patients (22 females and 30 males) with cerebral CM referred to our department underwent high-precision single-dose SRS using a LINAC with 6-MV photons. All patients had at least 1 bleeding episode prior to radiosurgery along with related symptoms. Median dose prescribed to the 85% to 95% isodose line encompassing the target volume was 15 Gy (range, 10-20).
Out of the total 52 patients, follow-up data were available for 47 patients (90.4%). Median age was 35 years (range, 19-63). Median follow-up time was 5.17 years (range, 0.08-9.5) after SRS. Three hemorrhages were identified in the post-SRS period. Statistically significant decrease was observed in the annual hemorrhage rate after radiosurgical treatment (pre-SRS 39% vs post-SRS 1.21, P < .0001). Overall, there were no radiosurgery-related complications resulting in mortality.
LINAC-based SRS may be considered as a treatment option for high-risk, symptomatic cerebral CM of selected patients with prior bleeding from lesions located at surgically inaccessible or eloquent brain areas.
手术是可安全切除的出血性和有症状的海绵状血管畸形的主要治疗方法。然而,基于直线加速器(LINAC)的立体定向放射外科(SRS)在高危、有症状的海绵状血管瘤病变管理中的作用仍有待进一步明确。在本研究中,我们评估了基于LINAC的SRS治疗脑海绵状血管畸形(CMs)的效果,并报告我们15年的单中心经验。
这是一项回顾性研究,数据来自1998年4月至2013年6月安卡拉古尔汗军事医学院和医学院放射肿瘤学系及神经外科。
52例患有脑海绵状血管畸形的患者(22例女性,30例男性)转诊至我科,使用配备6兆伏光子的LINAC接受了高精度单次剂量SRS治疗。所有患者在放射外科治疗前至少有1次出血事件及相关症状。规定给予包含靶体积的85%至95%等剂量线的中位剂量为15 Gy(范围10 - 20)。
52例患者中,47例(90.4%)有随访数据。中位年龄为35岁(范围19 - 63岁)。SRS后中位随访时间为5.17年(范围0.08 - 9.5年)。在SRS后期间发现3次出血。放射外科治疗后年出血率有统计学显著下降(SRS前39% vs SRS后1.21,P <.0001)。总体而言,没有导致死亡的放射外科相关并发症。
对于位于手术难以到达或脑功能区的病变且有过出血的特定高危、有症状的脑海绵状血管畸形患者,基于LINAC的SRS可被视为一种治疗选择。